Oct 26, 2007 On October 12, 2007, Victor Acquisition Corp., an indirect wholly owned subsidiary of PerkinElmer, Inc., commenced a tender offer to acquire all outstanding shares of common stock of ViaCell, Inc., at a price of $7.25 per share, in cash, pursuant to a previously announced Agreement and Plan of Merger among PerkinElmer, Inc., Victor Acquisition Corp. and ViaCell, Inc., dated October 1, 2007. The tender offer and any withdrawal rights to which ViaCell's stockholders may be entitled will expire at 12:00 midnight, New York City time, at the end of November 8, 2007, unless the offer is extended.
About ViaCell
ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. ViaCell markets ViaCord, a product offering through which families can preserve their baby's umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases.
ViaCell is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(SM), a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs.
ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell's pipeline is focused in the areas of cancer, cardiac disease, and diabetes. Additional information about ViaCell is available online at http://www.viacellinc.com. Additional information about ViaCord is also available at http://www.viacord.com.
